NewAmsterdam Pharma (NAMS) Accumulated Expenses (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 71.66% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 71.66% YoY), and the FY2025 full-year result was $15.4 million, up 76.84% from the prior year.
• Accumulated Expenses eased to $2.3 million in Q1 2026, from $15.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.4 million in Q4 2025 to a low of $2.3 million in Q1 2026.
• A 5-year average of $6.9 million and a median of $5.9 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 1197.34% in 2022 and slumped 71.66% in 2026, its largest moves.
• Tracing NAMS's Accumulated Expenses over 5 years: stood at $5.6 million in 2022, then plunged by 39.2% to $3.4 million in 2023, then surged by 157.71% to $8.7 million in 2024, then jumped by 76.84% to $15.4 million in 2025, then tumbled by 85.26% to $2.3 million in 2026.
• Business Quant data shows NAMS's Accumulated Expenses at $2.3 million in Q1 2026, $15.4 million in Q4 2025, and $5.9 million in Q3 2025.